David Langleben
Expertise in
2
conditions

David Langleben

Montreal, QC, CA 
Expertise in
2
conditions
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

David Langleben practices in Montreal, Canada. Mr. Langleben is highly rated in 2 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Hypertension, Pulmonary Embolism, Low Blood Pressure, and Lung Transplant.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Montreal, QC, Canada
Other Locations
Montreal, Canada
Quebec, QC, Canada
St. Michael's Hospital, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Enrollment Status: Terminated
Publish Date: January 31, 2025
Intervention Type: Biological
Study Drug: Autologous EPCs transfected with human eNOS
Study Phase: Phase 2/Phase 3
Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
Enrollment Status: Withdrawn
Publish Date: March 03, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 2 Less Clinical Trials

86 Total Publications

Corrigendum to ''Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials'' [The Journal of Heart and Lung Transplantation, 44 (2025) 135-146].
Corrigendum to ''Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials'' [The Journal of Heart and Lung Transplantation, 44 (2025) 135-146].
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: April 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Langleben's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile